Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Macy’s (M) delayed its Q3 earnings release after identifying
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Macy’s (M) delayed its Q3 earnings release after identifying
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
הפירמה חושבת שהציפיות הכלליות ל-Elevidys הן גבוהות מדי. ההערכה הקונצנזוסיאלית של 2.14 מיליארד דולר בשנת 2025 נראית כאופטימית מדי, בהתחשב בתוצאות הקליניות הצנועות של המוצר עד כה ובהוכחות המוגבלות התומכות
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Sarepta (SRPT) with a Sell rating and $80 price target The firm considers Elevidys consensus estimates to be too high. Elevidys consensus
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $197.00. The company’s shares closed yesterday at